Savant Capital LLC Increases Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Savant Capital LLC grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 54.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,993 shares of the biotechnology company’s stock after acquiring an additional 17,573 shares during the period. Savant Capital LLC’s holdings in BioCryst Pharmaceuticals were worth $448,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter worth $32,000. Family Legacy Financial Solutions LLC purchased a new stake in BioCryst Pharmaceuticals in the second quarter worth about $72,000. New Age Alpha Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter worth about $62,000. R Squared Ltd raised its stake in shares of BioCryst Pharmaceuticals by 84.2% in the first quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock worth $88,000 after buying an additional 5,335 shares during the period. Finally, Allianz Asset Management GmbH lifted its position in shares of BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 1,200 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $7.08 on Monday. The company’s fifty day moving average price is $7.33 and its 200-day moving average price is $8.63. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.31. The company has a market capitalization of $1.49 billion, a PE ratio of -39.33 and a beta of 1.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The business had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. The business’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.07) EPS. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on BCRX shares. JMP Securities raised their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 15th. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald lifted their target price on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.